Apogee Therapeutics, Inc. (APGE)

In the past six months, Apogee Therapeutics' stock experienced a public offering in October 2025, resulting in gross proceeds of $345 million. The Q3 2025 earnings showed a loss of ($1.14) per share, missing the consensus estimate. Apogee announced positive interim Phase 1 results from a healthy volunteer trial of APG333 on November 10, 2025, and positive interim results from the Phase 1b trial of Zumilokibart (APG777) in patients with mild-to-moderate asthma on January 6, 2026. BTIG reiterated a "Buy" rating for APGE on February 2, 2026, while Jefferies cut its target price to $95 from $98 on the same day, and RBC Capital downgraded Apogee Therapeutics on January 23, 2026. The stock has a consensus rating of "Moderate Buy," with an average price target of $104.58. There have been several insider sales reported, exceeding $409,524 in the last 90 days. APGE stock has shown a 75.93% increase over the last six months, but has fallen by -19.38% in the past month and -8.82% in the past week, reaching its all-time high of $84.56 on January 13, 2026.

As a clinical-stage biotechnology company, Apogee Therapeutics' products are in the development phase and not yet commercially available, so there is no current demand seasonality for its products and services. The demand at this stage is primarily from the medical community and investors for successful clinical trial outcomes and regulatory approvals, which are not subject to seasonal fluctuations.

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for inflammatory and immunological diseases. The company aims to create next-generation antibody drugs with superior efficacy, longer half-life, and improved patient convenience. Apogee's pipeline includes product candidates such as APG777 (Zumilokibart) for atopic dermatitis, asthma, and EoE; APG990 for atopic dermatitis; APG333 for asthma and COPD; APG808 for Type 2 allergic diseases; and APG279 for atopic dermatitis.

Apogee Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States. The company has research and development operations and collaborates with academic centers and contract research organizations in North America and Europe.

Apogee Therapeutics' brand reputation is tied to its clinical progress and analyst sentiment. The company has a "Moderate Buy" consensus rating from Wall Street analysts. Positive clinical trial results and a successful public offering enhance the company's reputation. Analyst downgrades and insider sales could temporarily impact reputation, while missing earnings estimates can put downward pressure on the stock.

Apogee Therapeutics, Inc. has a significant institutional ownership base, with 344 institutional owners and shareholders holding a total of 67,416,069 shares as of January 30, 2026. Major institutional owners include VR Adviser, LLC, Fmr Llc, Wellington Management Group Llp, Vanguard Group Inc, RTW Investments, Lp, BlackRock, Inc., Driehaus Capital Management Llc, Fairmount Funds Management LLC, and State Street Corp.